Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma.

Lisa May Ling Tachiki,Daniel S Hippe,Karly Williams Silva,Evan Thomas Hall,William McCamy,Dane Fritzsche,Andrea Perdue,Julia Majovski,Thomas Pulliam,Daniel A Goldstein,Joshua Veatch,Joel Ho,Paul T Nghiem,John A Thompson,Shailender Bhatia

Cancer immunology, immunotherapy : CII（2023）

引用 0|浏览11

暂无评分

摘要

ICI administration at RFD can allow extension of treatment duration, while preserving efficacy and reducing logistical and financial burden. RFD approach deserves further exploration in prospective clinical trials.

查看译文

关键词

Immunotherapy, Nivolumab, Pembrolizumab, Melanoma, Merkel cell carcinoma, Drug costs

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要